

Saft, Carsten, Prof. Dr. med.

Neurologische Klinik, Ruhruniversity
St. Josef- und St. Elisabeth- Hospital gGmbH
Huntington-Center NRW
Research department "Neurodegeneration"
Phone: +49 (0)234 509-2703

Gudrunstrasse 56
44791 Bochum

Phone: +49 (0)234 509-6405
Email: carsten.saft@ruhr-uni-bochum.de



General information

Date of Birth: 26.10.1965

Married, one daughter

Current pos.: Head of the Huntington Center North Rhine-Westphalia (NRW, clinical part),
Assistant medical director for movement disorders

Academic education with degree

- 02/2013 Professor of Neurology (APL), Department of Neurology, Ruhr-University Bochum
- 01/2007 Habilitation/Venia Legendi (Neurology) – Faculty of Medicine, Ruhr-University Bochum
- 11/2004 Board Certification in Neurology
- 1988-1996 Medical School, University of Mainz and Münster, Germany; Philadelphia, USA

Professional career

- 02/2007 W2 - foundation professorship "Neurogenetik" Teva Pharma GmbH, 3 years (225.000 € total)
- 07/2006 Head of the Huntington Center North Rhine-Westphalia (NRW, clinical part), Assistant medical director for movement disorders
- 05/03-04/04 Resident at the Department of Psychiatry, Westfälische-Wilhelms University, Münster
- 04/02-04/03 Project manager "Neurowissenschaften/ multiple Sklerose", Gemeinnützige Hertie-Stiftung (Foundation), Frankfurt am Main
- 01/1997 Resident at the Department of Neurology, St. Josef Hospital, Ruhr-University Bochum
- 08/96-11/96 Resident at the Institute of Experimental Epilepsy Research, Westfälische Wilhelms-Universität, Münster

Other

- 05/2014 steering committee, HD Training Platform (CHDI)
- Since 09/14 Elected member of the „Scientific and Bioethics Advisory Committee (SBAC)" of the European Huntington Disease Network
- 01/2013 steering committee "REGISTRY", study of the European Huntington's Disease Network (EHDN).
- 06/2013 steering committee, Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in HD: A prospective, randomized, controlled multi-centre study.
- Since 2010 Lead author of the Guidelines Committee "Huntington's Disease / Chorea" of the German Society of Neurology
- 12/2006 Pfizer-Research Award

12/97 Award of the University Münster for doctoral thesis "Antiepileptic effects of cobalt, manganese and magnesium on bicuculline-induced epileptiform activity in hippocampal neurons"; note: summa com laude

Research interest: Huntington's disease

Journal Editor:

International Editorial Review Board - Journal of Epidemiological Research

Editorial board of the Journal of Huntington's Disease

Sub-Investigator / Independent rater:

	Start/End
Ropinirole in Parkinson's Disease, Phase III	1997/1998
Pramipexole Eye Safety Study in Parkinson's Disease, Phase III	1998
Riluzole in Parkinson's Disease / Lab-Monitor, Phase III	2002
Budipine in Parkinson's Disease, Phase III	1997/1999
Riluzole in Huntington's Disease, Phase III	1999/2004
Amaril, Ethyl-EPA in Huntington's Disease (HD) , Phase III	2006/2007
Latrepirdin in Huntington's Disease (HD), Phase III – Independent rater	2009/2011
EURO-HD, Registry-Natural History Study in Huntington's Disease (HD)	2004/2009

Principle-Investigator:

Neurosearch, ACR-16 in HD, MERMAID, Phase III	2008/2009
Novartis Huntington Study Phase II AFQ056	2009/2011
EURO-HD, Registry-Natural History Study in Huntington's Disease (HD)	2009/2014
EURO-HD, Registry - Lifestyle Substudie	2011/2014
EURO-HD, Registry - Juvenile Substudie	2011/2014
EURO-HD, Registry - Irritability Substudie	2011/2014
EURO-HD, Registry - Frsbe Substudie	2011/2014
EURO-HD, Registry - QoL Substudie	2011
Mito-NET Natural History Study, Mitochondriopathy	2010/2015
Paddington, SEN 0014196 in Huntington's Disease, Phase 1b	2011/2012
ETON, Epigallocatechin in Huntington's Disease HD (IIT J Priller Charité), P II	2011/2014
Action HD, Bupropion in Huntington's Disease (IIT J Priller Charité), Phase III	2011/2014
SEN 0014196 in Huntington's Disease (NeuroSearch, Phase IIa	2011/2013
ENROLL-HD (Natural History Study in Huntington's Disease)	2014
PRIDE-HD, TEVA, Pridopidine in Huntington's Disease; Phase II	2014
PRIDE-HD OPEN Follow up	Preparation
Pfizer PDE10, PF-02545920 in Huntington's Disease Phase II	2015
LEGATO, TEVA (Laquinimod in Huntington's Disease) Phase II	2015
Pilotstudy - Deep Brain Stimulation of the Globus Pallidus in HD	2009/ 2012
Deep Brain Stimulation of the Globus Pallidus in HD	2015
IPSEN PHARMA S.A.S; P IIa in Huntington's Disease; Referral Neurologist	2015
Civitas CVT 301-005 in Parkinson's disease (2. Rater)	2015
Brexiprazzole, Agitation Associated With Alzheimer's Disease (Otsuka)	2015
ISIS HTTRx Antisense in early Huntington's Disease	2015

H-Index: 22

Cumulative Impact factor: 603,7

Carsten Saft

24.December.2015

5 most important publications within the last 5 years

1. **Saft C**; What is the Course of Huntington's Disease; Comment, The Lancet Neurology; Volume 13, Issue 12, Pages 1165 - 1166, December 2014
2. Carroll JB, Bates GP, Steffan J, **Saft C**, Tabrizi SJ. Treating the whole body in Huntington's Disease, Lancet Neurology in press
3. Beste C, Stock AK, Ness V, Hoffmann R, **Saft C**. Evidence for divergent effects of neurodegeneration in Huntington's disease on attentional selection and neural plasticity: implications for excitotoxicity. Brain Struct Funct. 2015 May;220(3):1437-47.
4. Stüwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, **Saft C**. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology. 2013 Feb 19;80(8):743-6
5. Beste C, Wascher E, Dinse HR, **Saft C**. Faster perceptual learning through excitotoxic neurodegeneration. Curr Biol. 2012 Oct 23;22(20):1914-7.

Publikationsliste - Carsten Saft -

Medline listed:

Carroll JB, Bates GP, Steffan J, **Saft C**, Tabrizi SJ
Treating the whole body in Huntington's Disease
Lancet Neurol in press
(IF 21.82)

Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, Rosser A, **Saft C**, Südmeyer M, Ohmann C, Schnitzler A, Vesper J; Surgical Approaches Working A
Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease.
Group of the European Huntington's Disease Network (EHDN).
Front Neurol. 2015 Aug 18;6:177.

Saft C

What is the Course of Huntington's Disease
Comment, Lancet Neurol. 2014 Dec;13(12):1165-6.
(IF 21.82)

Valcárcel-Ocete L, Alkorta-Aranburu G, Iriondo M, Fullaondo A, García-Barcina M, Fernández-García JM, Lezcano-García E, Losada-Domingo JM, Ruiz-Ojeda J, Álvarez de Arcaya A, Pérez-Ramos JM, Roos RA, Nielsen JE, **Saft C**; REGISTRY investigators of the European Huntington's Disease Network, Zubiaga AM, Aguirre A.
Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.
PLoS One. 2015 Jul 6;10(7):e0131573.
(IF 3.23)

Reilmann R, Rouzade-Dominguez ML, **Saft C**, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.

A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease.

Mov Disord. 2015 Mar;30(3):427-31.

(IF 5.68)

Saft C, Hoffmann R, Strassburger-Krogias K, Lücke T, Meves SH, Ellrichmann G, Krogias C. Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.

J Neural Transm. 2015 Jun;122(6):825-33.

(IF 2.87)

Rusz J*, **Saft C***, Schlegel U, Hoffman R, Skodda S

Phonatory Dysfunction as a Potential State Biomarker in Premanifest Huntington Disease

PLoS One. 2014 Nov 19;9(11):e113412

*contributed equally

(IF 3.23)

Lee DH, Heidecke H, Schröder A, Paul F, Wachter R, Hoffmann R, Ellrichmann G, Dragun D, Waschbisch A, Stegbauer J, Klotz P, Gold R, Dechend R, Müller DN, **Saft C***, Linker RA* Detection of angiotensin II type 1 receptor auto-antibodies in Huntington's disease

Mol Neurodegener. 2014 Nov 15;9:49.

*contributed equally

(IF 5.29)

Saft C, Siglienti I, Gold R, Schlamann M, Hindy NE, Sure U, Forsting M.

High noon back pain- severe pseudoradicular pain as a lead symptom of superficial siderosis: a case report.

Ther Adv Neurol Disord. 2014 Nov;7(6):276-8.

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, **Saft C**, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium. An Exploratory Double blind, Randomised Clinical Trial with Selisistat, a SirT1 Inhibitor, in Patients with Huntington's Disease.

Br J Clin Pharmacol. 2015 Mar;79(3):465-76.

(IF 3.69)

Ness V, Bestgen AK, **Saft C**, Beste C.

Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study.

J Huntingtons Dis. 2014;3(1):33-43.

Beste C, Humphries M, **Saft C**.

Striatal disorders dissociate mechanisms of enhanced and impaired response selection – Evidence from cognitive neurophysiology and computational modelling.

Neuroimage Clin. 2014 Apr 12;4:623-34.

(IF 2.53)

Beste C, Mückschel M, Elben S, J Hartmann C, C McIntyre C, **Saft C**, Vesper J, Schnitzler A, Wojtecki L.

Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease.

Brain Struct Funct. 2015 Jul;220(4):2441-8.

(IF 4.57)

Beste C, **Saft C**.

Benign hereditary chorea as an experimental model to investigate the role of medium spiny neurons for response adaptation.

Neuropsychologia. 2014 Jul;59:124-9.
(IF 3.45)

Reick C, Ellrichmann G, Thöne J, Scannevin RH, **Saft C**, Linker RA, Gold R.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Exp Neurol. 2014 Jul;257:50-6.
(IF 4.62)

Hoffmann R, Stüwe SH, Goetze O, Banasch M, Klotz P, Lukas C, Tegenthoff M, Beste C, Orth M, **Saft C**.
Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease.
Mov Disord. 2014 May;29(6):831-4.
(IF 5.68)

Beste C, Stock AK, Ness V, Hoffmann R, **Saft C**.
Evidence for divergent effects of neurodegeneration in Huntington's disease on attentional selection and neural plasticity: implications for excitotoxicity.
Brain Struct Funct. 2015 May;220(3):1437-47.
(IF 4.57)

Matusch A, **Saft C**, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A.
Cross sectional PET study of cerebral adenosine A_{2A} receptors in premanifest and manifest Huntington's disease. *contributed equally
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1210-20.
(IF 5.38)

Skodda S, Schlegel U, Hoffmann R, **Saft C**.
Impaired motor speech performance in Huntington's disease.
J Neural Transm. 2014 Apr;121(4):399-407.
(IF 2.87)

Saft C, Andrich JE, Müller T, Becker J, Jackowski J.
Oral and dental health in Huntington's disease - an observational study.
BMC Neurol. 2013 Sep 3;13:114.
(IF 2.49)

Beste C, **Saft C**.
Action selection in a possible model of striatal medium spiny neuron dysfunction: behavioral and EEG data in a patient with benign hereditary chorea.
Brain Struct Funct. 2015 Jan;220(1):221-8.
(IF 4.57)

Kloster E, **Saft C**, Akkad DA, Epplen JT, Arning L.
Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.
J Mol Med (Berl). 2014 Feb;92(2):177-84.
(IF 4.74)

Saft C, Leavitt BR, Epplen JT.
Clinical utility gene card for: Huntington's disease.
Eur J Hum Genet. 2014 May;22(5).
(IF 4.23)

Müller T, **Saft C**, Andrich J, Harati A.
Diadochokinetic movements differ between patients with Huntington's disease and controls.

NeuroRehabilitation. 2013;33(4):649-55.
(IF 1.73)

Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Nguyen HP. Collaborator.
The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.
PLoS One. 2013 Jul 22;8(7):e68951.
(IF 3.23)

Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Collaborator.
Suicidal ideation in a European Huntington's disease population.
J Affect Disord. 2013 Oct;151(1):248-58.
(IF 3.38)

Kloster E, **Saft C**, Epplen JT, Arning L.
CNR1 variation is associated with the age at onset in Huntington disease.
Eur J Med Genet. 2013 Aug;56(8):416-9.
(IF 1.49)

Beste C, Stock AK, Ness V, Hoffmann R, Lukas C, **Saft C**.
A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data.
Sci Rep. 2013;3:1797.
(IF 5.58)

Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, Reilmann R, **Saft C**, Roos RA; REGISTRY Investigators of the European Huntington's Disease Network.
Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease.
Mov Disord. 2013 Jul;28(8):1142-5
(IF 5.68)

Stüwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, **Saft C**.
Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.
Neurology. 2013 Feb 19;80(8):743-6.
(IF 8.30)

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; Registry investigators of the European Huntington's Disease Network. Collaborator.
 β -Defensin genomic copy number does not influence the age of onset in Huntington's Disease.
J Huntingtons Dis. 2013;2(1):107-24.

Neeve VC, Samuels DC, Bindoff LA, van den Bosch B, Van Goethem G, Smeets H, Lombès A, Jardel C, Hirano M, Dimauro S, De Vries M, Smeitink J, Smits BW, de Coo IF, **Saft C**, Klopstock T, Keiling BC, Czermin B, Abicht A, Lochmüller H, Hudson G, Gorman GG, Turnbull DM, Taylor RW, Holinski-Feder E, Chinnery PF, Horvath R.
What is influencing the phenotype of the common homozygous polymerase- γ mutation p.Ala467Thr?
Brain. 2012 Dec;135(Pt 12):3614-26.
(IF 10.23)

Saft C, Lissek S, Hoffmann R, Nicolas V, Tegenthoff M, Juckel G, Brüne M.
Mentalizing in preclinical Huntington's disease: an fMRI study using cartoon picture stories.
Brain Imaging Behav. 2013 Jun;7(2):154-62.
(IF 4.60)

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. Collaborator
A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.
JAMA Neurol. 2013 Jan;70(1):25-33.
(IF 7.35)

Beste C, Wascher E, Dinse HR, **Saft C**.
Faster perceptual learning through excitotoxic neurodegeneration.
Curr Biol. 2012 Oct 23;22(20):1914-7.
(IF 9.92)

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, **Saft C**, Landwehrmeyer GB, Orth M.
Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.
Hum Brain Mapp. 2012 Sep;33(9):2161-73.
(IF 6.92)

Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, **Saft C**, Landwehrmeyer GB, Orth M.
Default-mode network changes in preclinical Huntington's disease.
Exp Neurol. 2012 Sep;237(1):191-8.
(IF 4.62)

Abdulkadir A, Ronneberger O, Wolf RC, Pfeleiderer B, **Saft C**, Klöppel S.
Functional and structural MRI biomarkers to detect pre-clinical neurodegeneration.
Curr Alzheimer Res. 2013 Feb;10(2):125-34.
(IF 3.80)

Beste C, Ness V, Lukas C, Hoffmann R, Stüwe S, Falkenstein M, **Saft C**.
Mechanisms mediating parallel action monitoring in fronto-striatal circuits.
Neuroimage. 2012 Aug 1;62(1):137-46.
(IF 6.38)

Enzi B, Edel MA, Lissek S, Peters S, Hoffmann R, Nicolas V, Tegenthoff M, Juckel G, **Saft C**.
Altered ventral striatal activation during reward and punishment processing in premanifest Huntington's disease: a functional magnetic resonance study.
Exp Neurol. 2012 May;235(1):256-64.
(IF 4.62)

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG. Collaborator.
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant

fashion.

Neurology. 2012 Mar 6;78(10):690-5.

(IF 8.30)

Kerasnoudis A, Ellrichmann G, Gold R, **Saft C**.

Teaching Video Neurolmages: spinal and bulbar muscular atrophy mimicking essential tremor.

Neurology. 2012 Feb 7;78(6):e41.

(IF 8.30)

Föller M, Hermann A, Gu S, Alesutan I, Qadri SM, Borst O, Schmidt EM, Schiele F, vom Hagen JM, **Saft C**, Schöls L, Lerche H, Stournaras C, Storch A, Lang F.

Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis.

FASEB J. 2012 Apr;26(4):1526-34.

(IF 5.48)

Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Collaborator.

Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.

Mov Disord. 2012 Mar;27(3):439-42.

(IF 5.68)

Saft C, Andrich J, Fälker M, Gauda S, Kuchler S, Voitalla D, Goetze O.

No evidence of impaired gastric emptying in early Huntington's Disease.

PLoS Curr. 2011 Oct 25;3:RRN1284.

Stüwe SH, Goetze O, Arning L, Banasch M, Schmidt WE, Schöls L, **Saft C**.

Hepatic mitochondrial dysfunction in Friedreich ataxia.

BMC Neurol. 2011 Nov 15;11:145.

(IF 2.49)

de Yébenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, **Saft C**, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators.

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Neurol. 2011 Dec;10(12):1049-57.

(IF 21.82)

Saft C, Epplen JT, Wiczorek S, Landwehrmeyer GB, Roos RA, de Yébenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L.

NMDA receptor gene variations as modifiers in Huntington disease: a replication study.

PLoS Curr. 2011 Oct 4;3:RRN1247.

Beste C, Schüttke A, Pfeleiderer B, **Saft C**.

Music perception and movement deterioration in Huntington's disease.

PLoS Curr. 2011 Sep 20;3:RRN1252.

Beste C, Ness V, Falkenstein M, **Saft C**.

On the role of fronto-striatal neural synchronization processes for response inhibition—evidence from ERP phase-synchronization analyses in pre-manifest Huntington's disease gene mutation carriers.

Neuropsychologia. 2011 Oct;49(12):3484-93.

(IF 3.45)

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington's Disease Network. Collaborator
Discrepancies in reporting the CAG repeat lengths for Huntington's disease.
Eur J Hum Genet. 2012 Jan;20(1):20-6.

(IF 4.22)

Taherzadeh-Fard E*, **Saft C***, Akkad DA, Wiczorek S, Haghikia A, Chan A, Epplen JT, Arning L.
PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.

Mol Neurodegener. 2011 May 19;6(1):32.

*contributed equally

(IF 5.29)

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, **Saft C**, Landwehrmeyer GB, Orth M.

Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease.

J Cereb Blood Flow Metab. 2011 Sep;31(9):1908-18.

(IF 5.34)

Saft C, Reber D, Streuer M, Andrich J.
Post pump chorea in a 77-year-old male.
Neurol Sci. 2011 Aug;32(4):699-701.

(IF 1.50)

Brüne M, Blank K, Witthaus H, **Saft C**.
"Theory of mind" is impaired in Huntington's disease.

Mov Disord. 2011 Mar;26(4):671-8.

(IF 5.68)

Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, **Saft C**, Gold R, Linker RA.
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
PLoS One. 2011 Jan 31;6(1):e16172.

(IF 3.23)

Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, **Saft C***, Niphis D*.
Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography.

*contributed equally

J Psychiatry Neurosci. 2011 May;36(3):187-94.

(IF 7.49)

Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Collaborator

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.
J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12.

(IF 5.58)

Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network.
Collaborator

Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. Version 2. PLoS Curr. 2010 Sep 28

Taherzadeh-Fard E, **Saft C**, Wiczorek S, Epplen JT, Arning L.

Age at onset in Huntington's disease: replication study on the associations of ADORA2A,

HAP1 and OGG1.
Neurogenetics. 2010 Oct;11(4):435-9.
(IF 2.66)

Arning L, Haghikia A, Taherzadeh-Fard E, **Saft C**, Andrich J, Pula B, Höxtermann S, Wieczorek S, Akkad DA, Perrech M, Gold R, Epplen JT, Chan A.
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease.
J Mol Med (Berl). 2010 Apr;88(4):431-6.
(IF 4.74)

Henley SM, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J; EHDN Imaging Working Group. Collaborator.
Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease.
AJNR Am J Neuroradiol. 2010 Apr;31(4):711-9.
(IF 3.59)

Beste C, Willemsen R, **Saft C**, Falkenstein M.
Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects.
Neuropsychologia. 2010 Jan;48(2):366-73.
(IF 3.34)

Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA. Collaborator.
Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.
Neurology. 2009 Oct 20;73(16):1280-5.
(IF 8.30)

Andrich JE, Wobben M, Klotz P, Goetze O, **Saft C**.
Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain.
J Neural Transm. 2009 Dec;116(12):1607-11.
(IF 2.87)

Taherzadeh-Fard E, **Saft C**, Andrich J, Wieczorek S, Arning L.
PGC-1alpha as modifier of onset age in Huntington disease
Mol Neurodegener. 2009 Feb 6;4:10.
(IF 5.29)

Beste C, Willemsen R, **Saft C**, Falkenstein M.
Error processing in normal aging and in basal ganglia disorders.
Neuroscience. 2009 Mar 3;159(1):143-9.
(IF 3.33)

Beste C, Konrad C, **Saft C**, Ukas T, Andrich J, Pfeleiderer B, Hausmann M, Falkenstein M.
Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system - Evidence from event-related potentials.
Exp Neurol. 2009 Mar;216(1):148-57.
(IF 4.62)

Beste C, **Saft C**, Güntürkün O, Falkenstein M.
Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention.

J Neurosci. 2008 Nov 5;28(45):11695-702.
(IF 6.75)

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA; EHDI Study Group. Collaborator.
Weight loss in Huntington disease increases with higher CAG repeat number.
Neurology. 2008 Nov 4;71(19):1506-13.
(IF 8.30)

Arning L, Monté D, Hansen W, Wieczorek S, Jagiello P, Akkad DA, Andrich J, Kraus PH, **Saft C**, Epplen JT.
ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.
J Mol Med. 2008 Apr;86(4):485-90.
(IF 4.74)

Andrich J, Arning L, Wieczorek S, Kraus PH, Gold R, **Saft C**.
Huntington's disease as caused by 34 CAG repeats.
Mov Disord. 2008 Feb 28;23(6):879-881
(IF 5.68)

Beste C, **Saft C**, Andrich J, Gold R, Falkenstein M.
Response inhibition in Huntington's disease-A study using ERPs and sLORETA.
Neuropsychologia. 2008;46(5):1290-1297.
(IF 3.45)

Saft C, Schüttke A, Beste C, Andrich J, Heindel W, Pfeleiderer B.
fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease.
Neuropsychologia. 2008;46(5):1279-89.
(IF 3.45)

Beste C, **Saft C**, Andrich J, Gold R, Falkenstein M.
Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis.
J Neurophysiol. 2008 Mar;99(3):1213-23.
(IF 3.04)

Beste C, **Saft C**, Andrich J, Müller T, Gold R, Falkenstein M
Time processing in Huntington's disease: a Group Control Study
PLoS ONE. 2007 Dec 5;2(12):e1263
(IF 3.23)

Beste C*, **Saft C***, Yordanova J, Andrich J, Gold R, Falkenstein M, Kolev V.
Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease?
Neuropsychologia. 2007 Jul 2;45(13):2922-30. *contributed equally
(IF 3.45)

Arning L, **Saft C**, Wieczorek S, Andrich J, Kraus PH, Epplen JT.
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner.
Hum Genet. 2007 Sep;122(2):175-82.
(IF 4.52)

Beste C*, **Saft C***, Konrad C, Habel A, Schepers I, Jansen A, Pfeleiderer B, Falkenstein M
Levels of error processing in Huntington's Disease: a combined study using event-related potentials and voxel-based morphometry.

Hum Brain Mapp 2008 Feb;29(2):121-30.
(IF 6.92)

*contributed equally

Andrich J, **Saft C**, Ostholt N, Müller T
Assessment of simple movements and progression of Huntington's Disease
J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):405-7.
(IF 5.58)

Andrich J, **Saft C**, Ostholt N, Müller T
Complex movement behaviour and progression of Huntington's Disease
Neurosci Lett. 2007 Apr 18;416(3):272-4.
(IF 2.06)

Beste C*, **Saft C***, Andrich J, Gold R, Falkenstein M.
Error Processing in Huntington's Disease.
PLoS ONE. 2006 Dec 20;1(1):e86
(IF 3,23)

*contributed equally

Pechlivanis I, Andrich J, Scholz M, Harders A, **Saft C**, Schmieder K
Chronic subdural haematoma in patients with Huntington's disease
Br J Neurosurg. 2006 Oct;20(5):327-9.
(IF 0.95)

Mai M, Akkad AD, Wieczorek S, **Saft C**, Andrich J, Kraus PH, Epplen JT, Arning L.
No association between polymorphisms in the BDNF gene and age at onset in Huntington
disease.
BMC Med Genet. 2006 Nov 10;7(1):79.
(IF 2.45)

Bauer P, Kreuz FR, Burk K, **Saft C**, Andrich J, Heilemann H, Riess O, Schols L.
Mutations in TITF1 are not relevant to sporadic and familial chorea of unknown cause.
Mov Disord. 2006 Oct;21(10):1734-7.
(IF 5.63)

Saft C, Andrich J, Meisel NM, Przuntek H, Müller T
Assessment of simple movements reflects impairment in Huntington's Disease
Mov Disord. 2006 Aug;21(8):1208-12
(IF 5.63)

Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE.
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight
Huntington's
Disease patients: a case series.
BMC Neurol. 2006 Feb 28;6(1):11
(IF 2.49)

Hansen W, Saft C, Andrich J, Müller T, Wieczorek S, Epplen JT, Arning L.
Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on
age at onset of Huntington disease.
J Negat Results Biomed. 2005 Dec 22;4(1):12
(IF 1.47)

Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P, Baracca A, Cislighi G,
Saft C, Ragona G, Russo MA, Thompson LM, Solaini G, Fornai F.
Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington
disease mutation.

Mech Ageing Dev. 2006 Feb;127(2):217-20.
(IF 3.51)

Petrasch-Parwez E, **Saft C**, Schlichting A, Andrich J, Napirei M, Arning L, Wieczorek S, Dermietzel R, Epplen JT.

Is the retina affected in Huntington disease?
Acta Neuropathol (Berl). 2005 Nov;110(5):523-5.
(IF 10.76)

Saft C, Andrich J, Kraus PH, Przuntek H.
Der Einsatz von Amisulprid bei Patienten mit M. Huntington
Psychiatr Prax. 2005 Oct;32(7):363-6.
(IF 1.64)

Arning L, Kraus PH, **Saft C**, Andrich J, Epplen JT.
Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD).
BMC Med Genet. 2005 Oct 3;6(1):35
(IF 2.45)

Arning L, Kraus PH, Valentin S, **Saft C**, Andrich J, Epplen JT.
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.
Neurogenetics. 2005 Feb;6(1):25-8. Epub 2004 Nov 17.
(IF 2.66)

Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schöls L.
Mitochondrial impairment in patients and asymptomatic gene carriers of Huntington's disease. A magnetic resonance spectroscopy study
Mov Disord. 2005 Jun;20(6):674-9.
(IF 5.63)

Saft C, Andrich J, Przuntek H, Müller T, Stücker M
Segmentale Schweißsekretionsstörung bei MSA
[Segmental dysfunction of sweating in multiple system atrophy.]
Hautarzt. 2005 Aug;56(8):773-777.
(IF 0.54)

Saft C, Andrich J, Neuen-Jacob E, Schmid G, Schols L, Amoiridis G
Supracubital perineurioma of the median nerve misdiagnosed as carpal tunnel syndrom
BMC neurology 2004, 4:19
(IF 2.49)

Saft C, Andrich J, Brune N, Gencik M, Kraus PH, Przuntek H, Epplen JT
Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1692-1696
(IF 5.58)

Andrich J, **Saft C**, Gerlach M, Schneider B, Arz A, Kuhn W, Müller T.
Coenzyme Q10 levels in Huntington's Disease
J Neural Transm Suppl. 2004;(68):111-6.
(IF 1.07)

Brune N, Andrich J, Gencik M, **Saft C**, Müller T, Valentin S, Przuntek H, Epplen JT
MTHFR Polymorphisms in Huntington's Disease
J Neural Transm Suppl. 2004;(68):105-10.

(IF 1.07)

Saft C, Andrich J, Meisel NM, Przuntek H, Müller T
Congruent deterioration of complex and simple movements in patients with Huntington's Disease
J Neural Transm Suppl. 2004;(68):97-104.

(IF 1.07)

Arning L, Jagiello P, Wieczorek S, **Saft C**, Andrich J, Epplen JT.
Glutathione S-Transferase Omega 1 variation does not influence age at onset of Huntington's disease.
BMC Med Genet. 2004 Mar 24;5(1):7.

(IF 2.45)

Andrich J, **Saft C**, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W, Muller T.
Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
Mov Disord. 2004 Feb;19(2):226-8.

(IF 5.63)

Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, **Saft C**, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB.
Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study.
J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213-20.

(IF 5.58)

Saft C, Andrich J, Meisel NM, Przuntek H, Muller T.
Assessment of complex movements reflects dysfunction in Huntington's disease.
J Neurol. 2003 Dec;250(12):1469-74.

(IF 3.84)

Saft C, Andrich J, Stücker M, Przuntek H, Müller T.
Asymmetric anhidrosis in MSA.
Neurology. 2003 Jul 22;61(2):231.

(IF 8.30)

Andrich J, Schmitz T, **Saft C**, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW.
Autonomic nervous system function in Huntington's disease.
J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):726-31.

(IF 5.58)

Müller T, Voitalla D, **Saft C**, Kuhn W.
Levodopa in plasma correlates with body weight of parkinsonian patients
Parkinsonism Relat Disord. 2000 Jul 1;6(3):171-173.

(IF 4.13)

Not Medline listed:

Beste C, Schüttke A, Konrad C, **Saft C**, Andrich J, Pfeleiderer B
Functional connectivity during auditory processing in Huntington's Disease
The Journal of Psychophysiology. Volume 22, Number 4 / 2008, 195-201

(IF 1.43)

Reviews (Medline listed):

Epplen JT, Gencik M, Epplen A, Andrich J, **Saft C**, Przuntek H.
Morbus Huntington – a human genetic model disease
Cytogenet Cell Genet. [heute: Cytogenetic Genome Res.] 2000;91(1-4):90-6.

Ellrichmann G, Reick C, **Saft C**, Linker RA.
The role of the immune system in Huntington's disease.
Clin Dev Immunol. 2013;2013:541259.
(IF 2.93)

Reviews (Not Medline listed):

Saft C, Kosinski C, Landwehrmeyer GB
Fortschritte in Früh- und Verlaufsdagnostik bei Morbus Huntington
Akt Neurol. 01/2009; 36(10):506-523.
(IF 0.32)

Susmuth SD, **Saft C**, Reilmann R, Orth M, Landwehrmeyer GB
Was gibt es Neues bei der Huntington-Krankheit?
Huntington's disease update
Akt Neurol 2013; 40: 377–392
(IF 0.32)

Books

Saft C, Bär KJ, Bonelli RM, Burgunder JM, Dose M, Epplen JT, Jung HH, Kosinski C, Landwehrmeyer GB, Priller J, Reilmann R, Seppi K, Töpper R,
Federführender Autor der Leitlinien Chorea / Morbus Huntington der DGN, DGPPN und GfH
Leitlinien für Diagnostik und Therapie in der Neurologie. Leitlinien Chorea / Morbus Huntington

Amygdala (ISBN 980-953-307-188-1)
Chapter title: The ventral striatopallidum and extended amygdala in Huntington Disease
Petrasch-Parwez E, Habbes HW, Löbbbecke-Schumacher M, **Saft C** and Niescery J

Talks (Selection):

Morbus Huntington – prädiktive Diagnostik, medizinische und psychosoziale Betreuung von Patienten und Risikopersonen. „Klinik des M. Huntington mit Präsentation von Fallbeispielen – warum braucht man ein spezielles Zentrum?“
Vortrag im Rahmen der ärztlichen Fortbildung, auf Einladung, Fortbildungszentrum der LÄK C.
Hessen, Bad Nauheim, 29.09.2001

Chorea – Vorstellung der eigenen Forschergruppe
7.-10-03.2007

5. Deutscher Parkinsonkongress, Ulm

Educational Seminar Morbus Huntington

37th Int. Danube Symposium for Neurological Science and Continuing Education., 1th International Congress on ADHD
04.-05.06.2007, Würzburg

Modifier-Gene und Biomarker bei Morbus Huntington

1. Neurogenetik Symposium, St. Josef Hospital Bochum
09.02.2008, Fortbildungsveranstaltung der ÄKWL

Neue Erkenntnisse zur funktionellen Frühdiagnostik bei M. Huntington.
Frühe funktionelle Veränderungen und ihre klinischen Konsequenzen bei präsymptomatischen Mutationsträgern für M. Huntington.

11.09.2008, 81. Kongress der DGN, Hamburg, Minisymposium

Hyperkinetische Bewegungsstörungen.

6. Neurologisch – Psychiatrisches Kolloquium, Temmler ZNS.
17.-18.10.2008. Weimar

M. Huntington. Neurologie Symposium.

Marien-Hospital Euskirchen, Dr. med. Bauer, Temmler ZNS.
22.10.2008. Euskirchen

M. Huntington. Parkinson – Kongress Marburg.

Sateliten-Symposium Temmler Pharama ZNS.
06.03.2009. Marburg

M. Huntington – Frühdiagnostik, Modifier, Therapie und Differentialdiagnostik.

Vortragsreihe der Neurologischen Klinik Minden – Prof. Röther.
01.04.2009. Minden

Hyperkinetische Bewegungsstörungen. Psychiatrisches Kolloquium, Temmler ZNS.

25.11.2008. Siegen

Biomarker bei HD; 27.02.10; 15 Jahre HZ NRW; Bochum

M. Huntington – Biomarker, Phänotypen und Differentialdiagnosen, Düsseldorf,

Laborseminar Institut für Klinische Neurowissenschaften, Univ.- Prof. Dr. A. Schnitzler, Auf Einladung. 25.03.2010.

Saft C. Update - M. Huntington.

02.02.2011, Neurologie

Fortbildungsveranstaltungen im St. Marien-Hospital, Lünen

Saft C. Update - M. Huntington. Parkinson – Kongress Kiel. Sateliten-Symposium Temmler

Pharama ZNS. Auf Einladung. 11.03.2011. Kiel

Saft C. Differentialdiagnosen und Therapie choreatiformer Bewegungsstörungen.

Neurologische Fortbildung Universitätsklinikum Knappschafts Krankenhaus Bochum, Prof. Schlegel. 13.11.2012

Saft C. M. Huntington – update Therapie und Differentialdiagnose / aktuelle Studien und Forschungsansätze / Vortrag mit Videobeispielen

Ökumenisches Hainich Klinikum gGmbH, Prof. M. Jauß, 30.01.2013

M. Huntington. Therapie und laufende Studien – ein Update
C. Saft. Klinik für Neurologie, St. Josef-Hospital, Ruhr-Universität Bochum,
Wissenschaftliches Symposium für Mediziner und alle Interessierten
anlässlich des 20 – jährigen Bestehens des Huntington – Zentrums NRW, Bochum, 29. März
2014

Neurologische Klinik, RWTH Aachen, Direktor: Univ.-Prof. Dr. J. Schulz., Gemeinsame
Veranstaltung der Klinik für Neurologie, Klinik für Neurochirurgie, Klinik für Neuroradiologie
und Institut für Neuropathologie. Neurowissenschaftliches Seminar. Sommersemester 2014,
Dienstag, 06.05.2014, Update M. Huntington – Differential-diagnosen und Therapieansätze.

Bewegungsstörungen. Differentialdiagnose und Therapie der Chorea Huntington. Saft C.
Wermsdorf, Fachkrankenhaus Hubertusburg, 06.09.2014

Morbus Huntington - Beispiel für eine vererbte neurologische Erkrankung, Carsten Saft,
Brain Day 2014, 10.09.2014, Ruhr-Uni-Bochum, Sonderforschungsbereich 874, Integration
und Repräsentation sensorischer Prozesse

Hamburg, Fachgespräche Huntington, 18.10.2014, Desitin.

Choreatiforme Bewegungsstörungen. C Saft. Videoseminar. DGN - Jahreskongress 2014 in
München. 18.09.2014.

Hamburg, Fachgespräche Huntington, 18.10.2014, Desitin.

M. Huntington, Qualitätszirkel Oberhausen. Temmler. 24.03.2015

Das klinische Spektrum der Huntington Krankheit. C Saft. 9. Deutscher Parkinsonkongress.
17.April.2015, Berlin

Universitätsklinikum der RWTH Aachen, Huntington-Symposium, 25.04.2015, Aachen,
Leitliniengerechte pharmakologische Therapie

Expertenworkshop Huntington und Depression, Desitin Hamburg, 12.06.2015.

Hyperkinetische Bewegungsstörungen im Dialog. Erding. Huntington Zentrum Süd,
18.09.2015

M. Huntington – ein update. Krankenhaus St. Franziskus, Mönchengladbach,
Prof. Carl-Albrecht Haensch, 30.09.2015

DGN Minisymposium, Die Huntington-Krankheit eine neuropsychiatrische Herausforderung
neue Einsichten und Therapien in Entwicklung, 26.09.2015 (Vorsitz: Saft / Landwehrmeyer)

Intensivseminar Karlsruhe. M. Huntington. Prof. Gahn. 21.11.2015